Welcome to our dedicated page for Cyclacel Pharma SEC filings (Ticker: CYCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) SEC filings page on Stock Titan is intended to organize the company’s regulatory disclosures for investors who follow this clinical-stage biopharmaceutical issuer. Cyclacel develops cancer medicines based on cell cycle, epigenetics, transcriptional regulation and mitosis biology, and its filings with the U.S. Securities and Exchange Commission provide formal detail on this strategy, its lead PLK1 inhibitor plogosertib, and its capital structure.
In Cyclacel’s periodic reports such as Form 10-K annual reports and Form 10-Q quarterly reports, investors can typically review pipeline descriptions, risk factors and financial statements. The company has publicly discussed focusing development resources on the plogosertib clinical program, the deconsolidation and liquidation of its UK subsidiary Cyclacel Limited, and the resulting impact on research and development expenses and UK tax credits. These topics are usually expanded upon in management’s discussion and analysis sections of SEC filings.
Current Reports on Form 8-K are particularly relevant for tracking material events that Cyclacel has already described in press releases, such as private placements of Series F Convertible Preferred Stock with associated warrants, declarations of quarterly cash dividends on its 6% Convertible Exchangeable Preferred Stock, reverse stock splits of its common stock, and the Exchange Agreement with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd. Filings related to Nasdaq notices on minimum bid price compliance or changes to the company’s capital structure also appear in this category.
Stock Titan’s platform is designed to surface real-time updates from EDGAR so that new Cyclacel Forms 10-K, 10-Q, 8-K and any registration statements, such as a Form S-4 for the proposed exchange transaction, can be accessed as they are filed. In addition, investors can review ownership and insider activity through Forms 3, 4 and 5, where applicable, to understand how directors and officers transact in CYCC securities. AI-powered summaries on Stock Titan help explain the key points of lengthy filings, highlighting items such as clinical program focus, going concern discussions, financing arrangements and the status of strategic transactions, without replacing the need to read the full SEC documents.
Bio Green Med Solution, Inc. completed a major strategic pivot in 2025, exiting most drug development and becoming a Malaysia-focused supplier and trader of fire safety equipment through the acquisition of Fitters Sdn. Bhd. for 699,158 new common shares, equal to 19.99% of its stock.
The company deconsolidated its former R&D subsidiary Cyclacel Limited after a creditors’ voluntary liquidation, increasing stockholders’ equity by about $4.9 million, then repurchased and later sold its Plogosertib assets for up to $470,000. It raised $3.1 million via Series C and D preferred stock and later concentrated ownership in a new investor.
BGMS now distributes certified fire extinguishers, foam systems, PYRODOR fire doors, PPE and safety apparel into Malaysian commercial, industrial and government markets, but highlights substantial doubt about its ability to continue as a going concern, high customer concentration, intense competition, regulatory dependence and the need for additional capital.
Bio Green Med Solution, Inc. reported its first fire-safety product revenue after shifting away from biopharmaceuticals. For 2025, product revenue from fire safety equipment was $0.7 million, while net loss narrowed sharply to $3.0 million from $11.2 million in 2024.
Cash and cash equivalents were $3.5 million as of December 31, 2025, and the company expects existing cash to fund operations into the third quarter of 2026. Results reflect the September 2025 acquisition of Fitters Sdn. Bhd., liquidation of the U.K. subsidiary, and sale of the Plogosertib drug asset, which together produced a $4.9 million gain on deconsolidation and $0.3 million from the asset sale.
R&D expenses fell to $0.8 million for 2025 from $6.7 million in 2024 as legacy drug programs wound down, while general and administrative costs rose to $7.7 million due to one-time change-of-control expenses. A quarterly dividend of $0.15 per share was paid on the 6% Convertible Exchangeable Preferred Stock, and a warrant exchange triggered a large deemed dividend of $11.0 million to common shareholders.
Bio Green Med Solution, Inc. amendment to a Schedule 13G/A reports that Ong Yee Lung beneficially owns 0 shares of Common Stock, representing 0%. The filing provides the filers Malaysia citizenship and a signature dated 03/13/2026.
Bio Green Med Solution, Inc. amendment reports that Kua Khai Loon beneficially owns 0 shares of Common Stock (par value $0.001) representing 0% of the class as of 12/31/2025. The filing lists the reporter's Malaysia residence and provides related warrant exhibits.
Bio Green Med Solution, Inc. reports that Nasdaq will delist its 6% Convertible Exchangeable Preferred Stock (symbol BGMSP) after the security failed to regain compliance with the $1 million minimum market value of publicly held shares requirement by March 10, 2026. Nasdaq notified the company on March 12, 2026, that trading in the preferred shares is expected to be suspended at the opening of business on March 23, 2026, with delisting expected on or after April 2, 2026. The company does not plan to appeal and believes the preferred stock may be quoted and traded on the OTC Markets after delisting. The company states that this action does not affect its common stock, which continues to trade on the Nasdaq Capital Market under the symbol BGMS.